Pharma Pioneer

Theratechnologies Advances to Higher Dosage in Sudocetaxel Zendusortide Phase 1 Ovarian Cancer Trial

19 May 2024
2 min read

A biopharmaceutical firm, Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide, which is being tested on patients with advanced ovarian cancer. The Medical Review Committee (MRC) confirmed the safety of the initial dosage and endorsed the move to a higher dose as per the revised dose optimization strategy. Recruitment for the second group of patients is underway, with one individual already signed up and given the elevated dose.
The first part of the trial involved six patients, each receiving a dose of 1.75 mg/kg. For the subsequent group, the dosage has been increased to 2.50 mg/kg. The MRC's approval to begin the second group came after observing that the first group experienced no more than one dose-limiting toxicity. The study's protocol classifies dose-limiting toxicities as any Grade 3 or higher toxicity occurring within the first treatment cycle or any worsening of peripheral neuropathy to Grade 3 or 4 within three months.
Dr. Ira Winer, a trial investigator, expressed optimism regarding the drug's safety and tolerability in the initial group of patients. Theratechnologies' Senior Vice President and Chief Medical Officer, Christian Marsolais, Ph.D., highlighted the significance of advancing to the next dosage level as it aids in further defining the drug's potential as a viable treatment option for advanced ovarian cancer patients.
Sudocetaxel zendusortide represents a novel peptide-drug conjugate targeting the sortilin receptor (SORT1), which is linked to aggressive disease and poor prognosis in various cancers. The drug is currently in Phase 1 clinical trials, and Theratechnologies has developed the SORT1+ Technology™ platform to create more peptide-drug conjugates targeting SORT1.
Theratechnologies, listed on the TSX and NASDAQ, is dedicated to developing and commercializing innovative therapies to meet unmet medical needs. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
Pharma Pioneer
3 min read
Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
19 May 2024
Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.
Read →
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
Pharma Pioneer
3 min read
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
19 May 2024
Andelyn Biosciences has teamed up with Grace Science, LLC, to facilitate the technical transfer and production of GS-100, an AAV NGLY1 gene therapy for clinical trials.
Read →
Approval Granted to Brain Trust Bio for Phase I Trials of Novel IT Drug Delivery for ALS and CNS Conditions
Pharma Pioneer
2 min read
Approval Granted to Brain Trust Bio for Phase I Trials of Novel IT Drug Delivery for ALS and CNS Conditions
19 May 2024
Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials.
Read →
Astria Reports Favorable STAR-0215 Phase 1b/2 HAE Trial Outcomes
Pharma Pioneer
3 min read
Astria Reports Favorable STAR-0215 Phase 1b/2 HAE Trial Outcomes
19 May 2024
Astria Therapeutics has reported promising preliminary results from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.